Guggenheim upgrades Editas Medicine to Buy, sets $5 price target

Guggenheim upgraded Editas Medicine's stock to Buy with a price target of $5.00.The price target implies an upside of 71.2% from the Sep 22 close of $2.92.Key takeaways from the analyst notePositive Clinical Data for EDIT-401: Editas Medicine's ongoing development of EDIT-401 shows promising precli…